National Comprehensive Cancer Network
Pharmacy Program:
Educational Events & Programs
NCCN Task Force Report: Molecular Markers in Leukemia and Lymphoma
A presentation from the NCCN 14th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.
Presenters
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Seattle, Washington
Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York
Disclosure of Affiliations and Significant Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2 and 6) by experts on the topics.
The speakers listed below have disclosed that they have financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:
Jerald P. Radich, MD
Consultant: Bristol-Myers Squibb Company
Grant/Research Support: Bristol-Myers Squibb Company
Scientific Advisor: Bristol-Myers Squibb Company
Andrew D. Zelenetz, MD, PhD
Consultant: Abbott Laboratories; Cell Therapeutics, Inc.; Celgene Corporation; Cephalon, Inc.; Genentech, Inc.; GlaxoSmithKline
Grant/Research Support: Amgen Inc.; Genentech, Inc.; GlaxoSmithKline
Drs. Radich and Zelenetz have indicated that their presentations will not include discussion of investigational or unlabeled uses of commercial products.
The conference planner listed below has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:
William T. McGivney, PhD*
Advisory Board: Bristol-Myers Squibb Company
Consultant: Mattson Jack DiVinci
Speaker: Center for Business Intelligence; The Confera Group; Health Industry Group Purchasing Association; Japan Comprehensive Cancer Network, Breast; Johnson & Johnson Services, Inc.; Whistler Associates
*All proceeds donated to charitable causes.
The Conference Planning Staff had no financial interests to disclose.
NCCN: Alana L. K. Brody, MBA; Lynn Cherrin, MS; Patricia A. Daulerio; Mark Geisler; Patricia J. Goldsmith; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Lisa G. Kimbro, CPA, MBA; Jennifer L. McCann; Joan S. McClure, MS; Deirdre McKee, MPH; Diane McPherson; Liz Rieder; Shannon K. Ryan; Kelly C. Simpson; and Elizabeth L. Sweeney
Program Goal
The goal of this program is to provide participants with increased knowledge regarding the identification of molecular markers and chromosomal abnormalities in patients with leukemia and lymphoma.
Educational Objectives
Following this activity, participants should be able to:
- Summarize the findings of the NCCN Task Force for Molecular Markers in Leukemia and Lymphoma
- Describe various techniques used for the identification of molecular markers and chromosomal abnormalities, including their advantages and disadvantages
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 22, 2010. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 0.9 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: May 22, 2009
Expiration date: May 22, 2010
Commercial Support
Supported by an educational grant from Novartis Oncology
E-mail
Print
Mark
|
|
|
|
|
|
|
||